SGX - Singapore Exchange Ltd.



New Listings

Annual Report/Fin. Report

Company´s All-In-One Info

Research Reports

AGM Schedules

Prospectus/Circulars

Announcements

Stock/Indices List

ISIN Code Download

Corporate Info

Corporate Action

Warrants

Assistance Programme

Results Reporting

Market Statistics

Secondary Listings

Watchlist

Home » Listed Companies » Corporate Information


View Results By
By Company Name By Country By Market Corporate Distribution


  Corporate Information By Company Name :

   A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   0-9  


C & O PHARM TECH (HLDGS) LTD

Full Company Name:C & O Pharmaceutical Technology (Holdings) Limited
Incorporated in :BERMUDA
Incorporated on :28 Jul 2003
ISIN Code :BMG252991010
Registered Office :Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
Telephone:(1441) 295 1422
Fax:(1441) 292 4720
Secretary:Joanna Lim Lan Sim
Joey Chua Suk Yan
Link to Internet Websitehttp://www.changao.com

SHARE CAPITAL
-
Authorised Capital :HKD250,000,000 ordinary sharesPar Value :HKD0.250
Issued & Paid-up Capital :HKD165,840,000 Trading Currency :SGD

LISTINGS
Listed on 17 October 2005 on SGX Mainboard

REGISTRARS
Butterfield Fund Services (Bermuda) Limited (Bermuda)
Tricor Barbinder Share Registration Services (Singapore)

REGISTRAR ADDRESS
Butterfield Fund Services (Bermuda) Limited
Rosebank Centre
11 Bermudiana Road
Pembroke HM08
Bermuda

Tricor Barbinder Share Registration Services
8 Cross Street
#11-00 PWC Building
Singapore 048424


AUDITORS
KPMG

BACKGROUND
C & O Pharmaceutical Technology (Holdings) Limited was incorporated in Bermuda on 28 July 2003.

The Group's principal business activities are carried out in China and include research, manufacturing, marketing and distribution of C&O branded pharmaceutical products as well as distribution of third party pharmaceutical products in all the provinces of China. The Group's manufacturing facilities are located in Nanjing City, China.

The Group's current portfolio of products includes four imported pharmaceutical products and 24 C&O branded pharmaceutical products, most of which are included in the National Health Insurance Scheme. To sustain a continuous stream of new products launch, the Group maintains a development pipeline of over 50 new products. The Group is also working on 10 new compounds with the potential for international patent applications.

Currently, the Group's distribution network covers more than 3,000 distributors and over 300,000 clinics, pharmacies and hospitals across the whole of China.


Information Last updated on 07/04/2008 07:00:36 AM